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Objectives: Obesity is a known risk factor for type 2 diabetes (T2D). We conducted a case–control study to assess
the association between body mass index (BMI) and the risk of being diagnosed with T2D in the United States.
Methods: We selected adults (≥ 18 years old) who were diagnosed with T2D (defined by ICD-9-CM diagnosis codes
or use of anti-diabetic medications) between January 2004 and October 2011 (“cases”) from an electronic health
records database provided by an integrated health system in the Middle Atlantic region. Twice as many individuals
enrolled in the health system without a T2D diagnosis during the study period (“controls”) were selected based on
age, sex, history of cardiac comorbidities or hyperinflammatory state (defined by C-reactive protein and erythrocyte
sedimentation rate), and use of psychiatric or beta blocker medications. BMI was measured during one year prior to
the first observed T2D diagnosis (for cases) or a randomly assigned date (for controls); individuals with no BMI
measure or BMI < 18.5 kg/m2 were excluded. We assessed the impact of increased BMI (overweight: 25–29.9 kg/m2;
Obesity Class I: 30–34.9 kg/m2; Obesity Class II: 35–39.9 kg/m2; Obesity Class III: ≥40 kg/m2), relative to normal BMI
(18.5–24.9 kg/m2), on a T2D diagnosis using odds ratios (OR) and relative risks (RR) estimated from multiple logistic
regression results.
Results: We included 12,179 cases (mean age: 55, 43% male) and 25,177 controls (mean age: 56, 45% male). We
found a positive association between BMI and the risk of a T2D diagnosis. The strength of this association increased
with BMI category (RR [95% confidence interval]: overweight, 1.5 [1.4–1.6]; Obesity Class I, 2.5 [2.3–2.6]; Obesity Class
II, 3.6 [3.4–3.8]; Obesity Class III, 5.1 [4.7–5.5]).
Conclusions: BMI is strongly and independently associated with the risk of being diagnosed with T2D. The
incremental association of BMI category on the risk of T2D is stronger for people with a higher BMI relative to
people with a lower BMI.
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Diabetes, the most common metabolic disorder, is associ-
ated with substantial disease burden, including increased
mortality risk and significant long-term morbidity [1-4].
Diabetes was diagnosed in 22.3 million people (7% of the
population) in the United States (US) in 2012 and was re-
sponsible for $176 billion of direct medical costs and $69
billion of indirect (lost productivity) costs [5]. Type 2 dia-
betes mellitus (T2D) comprises about 90%–95% of all
diabetes cases [6,7], and its prevalence has been steadily
increasing [8]. Obesity, classified as body mass index
(BMI) ≥30 kg/m2, is a known predictor of T2D and has
become a major public health problem in the US [9], af-
fecting over one-third (35.7%) of the population [10]. It
costs about $190.2 billion (in 2005 dollars) annually to
treat obesity for the non-institutionalized US adult popu-
lation, which accounts for almost 21% of US healthcare
expenditures [11]. Healthcare costs attributable to obesity
and overweight in the US are projected to reach $860.7
billion by 2030 [12].
The impact of BMI classification, including overweight
and various grades of obesity, on the risk of T2D in the
real-world practice is a well-investigated topic [9,13].
However, the evidence for the US is dated, with most of
the studies relying on data before the year 2005 and does
not reflect recent changes in the obesity ‘epidemic’
[14-21]. We designed this case–control study to obtain
more recent evidence of the association between BMI
and the risk of being diagnosed with T2D in US.
Materials and methods
Data and Study Sample
Data were obtained from the MedMining® database, which
contains electronic health records from the Geisinger
Health System. The Geisinger Health System, which
serves more than 4 million individuals in the state of
Pennsylvania, is an integrated health system with an 880+
multi-specialty physician group practice, 5 hospital cam-
puses, 72 primary and specialty clinic sites, and a health
plan. Individuals’ health records, which have been kept in
electronic form at Geisinger Health System since 1996,
contain information on demographic characteristics (age,
sex, and race/ethnicity), encounter details from inpatient,
outpatient, and office-based settings (such as ICD-9-CM
diagnosis codes, and CPT-4 procedure codes), medication
orders, lab findings, and actual costs incurred by the
Geisinger Health System for those encounters. This data-
set has been widely used to address the health economic
evaluations in real-world settings.[22-26]
Cases were selected if their first diagnosis of T2D (de-
fined by ICD-9-CM diagnosis codes 250.x0 or 250.x2 or
by an anti-diabetic medication order, whichever came
first) while in the Geisinger Health System database was
observed between January 2004 and October 2011 (studyperiod). Events and measurements were anchored by
each individual’s “index date,” which was defined as the
date of their incident, or first observed, T2D diagnosis in
the MedMining database.
We used ICD-9-CM diagnosis codes and laboratory
values to measure the history of any cardiac comorbidi-
ties (lipid abnormalities, coronary heart disease, acute
myocardial infarction, angina pectoris, or hypertension),
hyperinflammatory state (defined by clinical biomarkers
of C-reactive protein and erythrocyte sedimentation rate),
psychiatric medication use (anticonvulsants or antipsychotic
medication), and beta-blocker medication use during each
case individual’s 12-month pre-index period.
We created a group of potential controls by randomly
selecting two individuals with no history of diabetes (de-
fined by ICD-9-CM diagnosis codes 250.xx or use of any
anti-diabetic medication) during the study period for each
case. Cases and potential controls were selected based
on age group (< 65 or ≥ 65), sex, and history of any car-
diac comorbidities, hyperinflammatory state, psychiatric
medication use, and beta-blocker medication use. Since
the potential controls never received a T2D diagnosis,
we assigned them a random index date between the be-
ginning and end of the study period. Individuals (both
cases and potential controls) were further required to
be alive as of October 31, 2011, be ≥18 years old at
index date, and satisfy all of the selection criteria listed
in the Appendix. Baseline BMI was defined as the last
value observed during the 12-month pre-index period
for both cases and controls, and was classified accord-
ing to the World Health Organization’s definition of BMI:
normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2),
Obesity Class I (30–34.9 kg/m2), Obesity Class II (35–
39.9 kg/m2), and Obesity Class III (≥40 kg/m2).
Analysis
We compared individual demographic and clinical char-
acteristics, including baseline BMI, between cases and
controls and assessed the statistical significance (p <
0.05) of the differences between groups using the Stu-
dent’s t-test for continuous variables and the chi-square
test for categorical variables.
We assessed the impact of baseline BMI on the risk of
T2D diagnosis via the odds ratios (ORs) estimated from
an unconditional multiple logistic regression model that
adjusted for other covariates such as the index year, smok-
ing status, employment status, payer status, Geisinger
Health Plan coverage, history of depression, use of se-
lected medications (to treat depression/anxiety, obesity,
hyperlipidemia, and hypertension) and medical burden
during the 12-month pre-index period. Medical burden
was measured by any use of outpatient, inpatient, or
emergency services, as well as the logarithm of the total
annual encounter costs adjusted to 2011 dollars using the
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cluded to address the fact that the age variable used in the
matching procedure was categorical (≥ 65 years or not). In
addition to the adjusted ORs, we estimated the adjusted
relative risk of T2D diagnosis for each BMI category (with
normal BMI as the comparator) using the method of
recycled predictions [28]; 95% confidence intervals (CIs)
around the relative risks were estimated by the 2.5 and
97.5 percentiles of 1,000 bootstrap replications [29]. Be-
cause we sampled cases and controls independent of ex-
posure status (i.e., BMI), which is consistent with the
case-cohort sampling approach, these relative risk esti-
mates are applicable to the whole Geisinger Health System
patient population [30]. Data were compiled and analyzed
using SAS (version 9.2, SAS Institute Inc., Cary, NC).
Results
We identified 25,241 individuals who experienced their in-
cident T2D diagnosis between January, 2004 and October,
2011, and 50,482 matched control individuals with no his-
tory of diabetes during the same time frame. The final
sample included 37,356 individuals who had a baseline
BMI ≥18.5 kg/m2 (12,179 cases and 25,177 controls) after
we applied the sample selection criteria (Figure 1). Table 1
displays the individuals’ demographic and clinical charac-
teristics. Compared with control individuals, the case indi-
viduals had higher baseline BMI values (mean ± standard
deviation: 35.4 ± 8.5 kg/m2 vs. 29.4 ± 6.3 kg/m2, p < 0.01).
Cases were more likely to be younger, male, and to haveFigure 1 Sample Selection.higher healthcare resource use as measured by costs dur-
ing the 12-month pre-index period than controls. Cases
were also more likely to have experienced comorbidities
related to diabetes and/or obesity and used medications
related to diabetes or obesity during the 12-month pre-
index period than controls.
As shown in the first 4 rows of Table 2 and in the upper
panel of Figure 2, compared with individuals with a normal
BMI, individuals who were overweight or obese were more
likely to be diagnosed with T2D (OR [95%CI]: ranging
from 1.6 [1.5–1.8] for overweight adults to 11.6 [10.5–12.8]
for adults in Obesity Class III, all p-values < 0.01). The rela-
tive risks displayed a similar pattern: the relative risk was
1.5 (95%CI: 1.4–1.6) for overweight adults, 2.5 (2.3–2.6) for
adults in Obesity Class I, 3.6 (3.4–3.8) for adults in Obesity
Class II, and 5.1 (4.7–5.5) for adults in Obesity Class III
(lower panel of Figure 2).
Furthermore, we found that the change in the magni-
tude of the ORs from one BMI category to the next was
larger for individuals in higher BMI categories than indi-
viduals in lower BMI categories, as illustrated by the in-
creasing slope of the lines connecting the ORs and, to a
lesser degree, the lines connecting the relative risks in
Figure 2. These patterns of ORs and relative risks imply
that individuals in higher BMI categories were increas-
ingly more likely to be diagnosed with T2D than individ-
uals in lower BMI categories (p < 0.05).
Other individual characteristics, aside from BMI, were
also significantly associated with the risk of being diagnosed
Table 1 Demographic and Clinical Characteristics of the
Analytic Sample






BMI (mean ± SD, kg/m2) 35.4 ± 8.5 29.4 ± 6.3 <0.01
BMI category (%) <0.01
18.5–24.9 kg/m2 7.4 24.1
25.0–29.9 kg/m2 20.5 36.1
30.0–34.9 kg/m2 26.3 23.3
35.0–39.9 kg/m2 20.6 10.0
40+ kg/m2 25.3 6.5
Age (mean ± SD) 55 ± 15.9 56 ± 18.2 <0.01



















Smoking status (%) <0.01
Never smoke 49.0 48.0
Former smoker 29.8 22.6
Current smoker 17.8 15.4
Other/unknown 3.4 14.0
Employment status (%) <0.01
Full Time 37.1 32.4
Not employed 22.2 15.5
Other/unknown 40.8 52.1





Table 1 Demographic and Clinical Characteristics of the
Analytic Sample (Continued)
Covered by Geisinger Health
Plan (%)
49.7 43.8 <0.01
Any cardiac comorbidities (%) 85.3 63.1 <0.01
Hyperinflammatory state (%) 6.3 2.1 <0.01
Depression (%) 8.2 4.1 <0.01
Psychiatric drugs (%) 14.7 7.7 <0.01
Antidepressants/anxiolytics (%) 36.5 22.4 <0.01
Anti-obesity drugs (%) 0.4 0.1 <0.01
Beta blockers (%) 32.3 21.4 <0.01
Antihyperlipidemia drugs (%) 36.7 23.1 <0.01
Antihypertensives (%) 35.2 21.1 <0.01
Any outpatient encounters (%) 95.8 88.3 <0.01











Data source: Geisinger Health System electronic health records, January
2004–October 2011.
Characteristics were measured at index date or during 1 year before
index date.
Any cardiac comorbidities: lipid abnormalities, coronary heart disease, acute
myocardial infarction, angina pectoris, and hypertension, were defined by
both ICD-9-CM diagnosis codes and clinical biomarkers.
Hyperinflammatory state: defined by clinical biomarkers of C-reactive protein
and erythrocyte sedimentation rate.
Psychiatric medication use: anticonvulsants or antipsychotic medication.
Total encounter costs: in 2011 dollars.
P value based on t-test for continuous variables and chi-squared test for
categorical variables.
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with 18–44 years old), were black or other race (compared
with white), or ever smoked (compared with never) were
associated with an increased risk of T2D diagnosis. In
addition, individuals who experienced comorbidities (any
cardiac comorbidities, hyperinflammatory state, or depres-
sion) or who used medications (psychiatric drugs, antide-
pressants or anxiolytics, antihyperlipidemia drugs, and
antihypertensives) were more likely to have been diagnosed
with T2D than those who did not, as were individuals with
more medical costs in the pre-index period. However, the
ORs of the individual characteristics (except for BMI) were
not the focus of this study since they were included in the
regression in order to adjust for the impact of BMI.
Discussion
After adjusting for a number of characteristics associated
with the risk of T2D, we found that, compared with nor-
mal BMI, overweight and obesity was statistically signifi-
cantly associated with the risk of being diagnosed
with T2D among individuals without any other prior evi-
dence of T2D. We further found that the risk of a T2D
Table 2 Logistic Regression for Risk of T2D Diagnosis
Odds Ratio 95% CI
BMI category (reference: 18.5–24.9 kg/m2)
25.0–29.9 kg/m2 1.63 1.49–1.78
30.0–34.9 kg/m2 3.19 2.92–3.48
35.0–39.9 kg/m2 5.86 5.32–6.46
40+ kg/m2 11.58 10.46–12.82
















Smoking status (reference: Never smoke)
Former smoker 1.18 1.11–1.25
Current smoker 1.15 1.07–1.23
Other/unknown 0.40 0.35–0.45
Employment status (reference: Full time)
Not employed 1.14 1.06–1.23
Other/unknown 1.08 1.01–1.16




Covered by Geisinger Health Plan 1.23 1.16–1.29
Any cardiac comorbidities 1.70 1.58–1.83
Hyperinflammatory state 2.08 1.83–2.37
Depression 1.14 1.02–1.27
Psychiatric drug 1.31 1.21–1.43
Antidepressants/anxiolytics 1.19 1.12–1.26
Anti-obesity drug 1.39 0.81–2.38
Beta blocker 1.04 0.98–1.10
Antihyperlipidemia drugs 1.38 1.30–1.47
Antihypertensives 1.32 1.24–1.40
Any outpatient encounters 0.66 0.57–0.76
Table 2 Logistic Regression for Risk of T2D Diagnosis
(Continued)
Any inpatient encounters 1.31 1.19–1.43
Any emergency department encounters 1.03 0.95–1.12
Log of total encounter costs 1.17 1.14–1.19
C statistic = 0.79
Data source: Geisinger Health System electronic health records, January
2004–October 2011.
Characteristics were measured at index date or during 1 year before
index date.
Any cardiac comorbidities: lipid abnormalities, coronary heart disease, acute
myocardial infarction, angina pectoris, and hypertension.
Hyperinflammatory state: defined by C-reactive protein and erythrocyte
sedimentation rate.
Psychiatric medication use: anticonvulsants or antipsychotic medication.
Total encounter costs: in 2011 dollars.
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higher BMI categories than for individuals in lower BMI
categories.
Our results are consistent with other studies that have
examined the association between BMI and risk of T2D
using nationally representative samples. For example,
using data from the 2001 Behavioral Risk Factor Surveil-
lance System, Mokdad et al. (2003) also found statisti-
cally significant and increasingly larger ORs for T2D
among overweight adults (1.59, 95% CI: 1.46–1.73),
adults with BMI between 30 and 39.9 kg/m2 (3.44, 95%
CI: 3.17–3.74), and adults with BMI ≥ 40 kg/m2 (7.37,
95% CI: 6.39–8.50) relative to adults with normal BMI
[20]. According to the Nurses’ Health Study, the adjusted
relative risk of T2D associated with each 5-unit increment
in BMI ranged from 1.55 (95% CI: 1.36–1.77) to 2.36 (95%
CI: 1.83–3.04) among women, depending on the partici-
pants’ race/ethnicity, in the 1980–2000 prospective cohort
[15]; and the overall relative risk of non-insulin-dependent
T2D among women with BMI ≥ 29.9 kg/m2 relative to
women with BMI ≤ 20.1 kg/m2 in the 1986–1994 cohort
was 11.2 (95% CI: 7.9–15.9) [14]. Although regional data
were used, the current study covered more recent years.
Moreover, BMI values were clinically measured in the
current study, compared with BMI calculated from self-
reported height and weight in those earlier studies. Self-
reported weight and height considerably underestimate
the individuals’ measured BMI [31,32] and may thus
have weakened the association between obesity and risk
of T2D and/or biased the estimated results. This may
explain the lower ORs associated with BMI levels in the
Mokdad et al. study, compared to the current study.
Our results are also consistent with the studies that
investigated the association between BMI and risk of
T2D among individuals with pre-diabetes. The Diabetes
Prevention Program (DPP) is a large randomized clinical
trial that ran from 1996 to 2001 (average follow-up:
2.8 years) and that enrolled individuals at higher risk for
T2D (all subjects had impaired glucose tolerance at
Figure 2 Odds Ratios and Relative Risks of T2D Diagnosis, by BMI Categories. Data source: Geisinger Health System electronic health
records, January 2004–October 2011. Odds ratios and 95% confidence intervals (CI) were estimated using logistic regression, adjusted for baseline
demographic and clinical characteristics. Relative risks were estimating using the method of recycled predictions and 95% CIs were estimated
from bootstrap replications. BMI categories: normal: 18.5–24.9 kg/m2; overweight: 25–29.9 kg/m2; Obesity Class I: 30–34.9 kg/m2; Obesity Class II:
35–39.9 kg/m2; Obesity Class III: ≥40 kg/m2.
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(95% CI: 48–66%) among subjects who were assigned to
the lifestyle-modification program (with a goal of at least
a 7% weight loss of the baseline body weight) than those
in the placebo group [33]. Additionally, weight loss
among subjects in the lifestyle-modification program
was significantly and independently associated with re-
ductions in blood glucose from pre-diabetic to normal
levels [34]. Weight loss was also associated with long-
term benefit in a follow-up study of the DPP program,
which found that the 10-year cumulative incidence of
T2D among participants in the lifestyle-modification
program was lower compared with those treated with
metformin or in the placebo group [35].The risk of T2D associated with each BMI level was esti-
mated, adjusting for other covariates. To assess the impact
of the other covariates, we estimated an unadjusted logistic
regression model (with BMI level as the only covariate);
the resulting ORs were 1.9 (95%CI: 1.7–2.0) for overweight,
3.7 (3.4–4.0) for Obesity Class I, 6.7 (6.2–7.4) for Obesity
Class II, and 12.7 (11.6–14.0) for Obesity Class III (all
p-values < 0.01). The unadjusted ORs were slightly higher
than the adjusted ORs. This implies that some factors,
such as age, are associated with both increased BMI and
increased risk of T2D, but the impact of these factors on
the association between BMI and risk of T2D is limited.
Besides the association between BMI and risk of T2D,
our study also revealed other interesting findings. For
Ganz et al. Diabetology & Metabolic Syndrome 2014, 6:50 Page 7 of 8
http://www.dmsjournal.com/content/6/1/50example, the BMI value considered in our study was
the last one observed during the 12 months before the
index date, which tended to be closer to the index date
among case individuals than control individuals (9.0 vs.
80.3 days, p < 0.01). This implies that individuals (and/or
their physicians) may have started monitoring their BMI
(and probably other clinical biomarkers) more frequently
when there were indications that they may be at risk of
developing T2D.
The risk of developing T2D for individuals who were
overweight or obese was about 1.5–5 times higher than
for individuals with normal BMI, as estimated in our
study. This demonstrates the importance of continu-
ous weight management, which not only can reduce
the disease burden of obesity but also may prevent fur-
ther progression to T2D. Weight management is par-
ticularly important for people with severe obesity, who
were disproportionally at higher risk of developing
T2D than individuals with less severe obesity. Physi-
cians should regularly monitor the weight of their pa-
tients with obesity.
Our results should be interpreted in light of the study’s
limitations. First, and foremost, the use of a retrospective
cohort design prevented us from understanding the causal
effect of BMI on the risk of developing T2D. Second,
although cases and controls were matched on broad
demographic and clinical characteristics (except for BMI
measures) while selecting them from the Geisinger Health
System database, the distribution of demographic and
baseline clinical characteristics between cases and controls
in our final analytic sample were not balanced. We ad-
dressed this imbalance by adjusting for a detailed list of
confounding factors, but the potential for unmeasured,
and unadjusted, confounding in baseline characteristics
may have remained. Another limitation is that Geisinger
Health System data cannot capture health services pro-
vided outside of the system. Without available enrollment
data, we considered individuals to have continuously
received care in the Geisinger Health System during the
12-month pre-index period if they had activity recorded in
365 or more days before the index date. This approach is
unlikely, we feel, to introduce substantial bias since there
is no evidence that the likelihood for individuals to seek
care outside of the Geisinger system was correlated with
T2D or obesity (personal communication, Christopher
Still and Thomas Graf). A similar approach has been used
in previous retrospective electronic health records data-
base studies [36,37]. Significant clinical and/or body size
differences between people with and without BMI mea-
sures may also serve as another potential source of bias.
Finally, the findings are based on data from a single inte-
grated health system caring for individuals in Pennsylvania
and may not be generalizable to larger populations and to
other regions in the US.Conclusion
Using a large cohort of individuals with detailed elec-
tronic health records, we were able to show that not
only is BMI strongly and independently associated with
the risk of being diagnosed with T2D, but also that the
magnitude of this positive association is larger for higher
BMI values. Further research on the association between
BMI and the risk of developing T2D should include the
time to the incident T2D diagnosis and, if data are avail-
able, account for individuals’ pre-diabetic status and the
timing and duration of obesity.
Appendix. Sample Selection Criteria
Case and control individuals needed to satisfy the fol-
lowing criteria:
 During their 12-month pre-index period they had
to have:◦ Continuously received care in the Geisinger
Health System (defined by having encounters that
occurred 365 or more days before the index date)
◦ Not be pregnant
◦ Not had bariatric surgery
◦ At least one valid BMI measurement
 Cases and controls were excluded if they had:
◦ Any BMI measurement <18.5 kg/m2 during the
12-month pre-index period
◦ Any evidence of type 1 diabetes, during the
study period, defined by▪ ICD-9-CM diagnosis codes of 250.x1 or 250.x3
▪ A medication order for insulin without a
diabetes diagnosis codeAbbreviations
BMI: Body mass index; CI: Confidence interval; DPP: Diabetes Prevention
Program; OR: Odds ratio; T2D: Type 2 diabetes; US: United States.
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